NATA Webinar – Heparin-induced thrombocytopenia (HIT)

Heparin-induced thrombocytopenia (HIT)

1/ How would I manage my patient with HIT requiring cardiac surgery?

Corinne Frère MD, PhD
Professor of Hematology
Sorbonne University
Assistance Publique–Hôpitaux de Paris
France

Learning objectives:

Review the ISTH guidance on managing patients with HIT requiring cardiac surgery with cardiopulmonary bypass,
Discuss available intraoperative anticoagulation strategie,
Emphasize the importance of individualized multidisciplinary decision-making and appropriate postoperative monitoring.

2/ How would I manage anticoagulation in my patient with suspected HIT in the ICU?

Jerrold H Levy, MD, FAHA, FCCM
Professor of Anesthesiology, Critical Care, and Surgery (Cardiothoracic)
Duke University School of Medicine
Adjunct Professor, Pathology and Laboratory Medicine, Centre for Blood Research, University of British Columbia
Chair, Scientific Subcommittees of the ISTH

Learning objectives:

Assess the clinical probability of HIT using the 4Ts score and appropriate laboratory testing,
Review evidence-based management of suspected HIT, including heparin discontinuation and selection of an appropriate direct thrombin inhibitor,
Examine argatroban and bivalirudin with respect to pharmacology, monitoring, organ-specific clearance, and clinical applications.